Last reviewed · How we verify
Polyhexanide
At a glance
| Generic name | Polyhexanide |
|---|---|
| Also known as | Prontoderm® Nasal Gel, Prontoderm® Foam |
| Sponsor | Swiss Paraplegic Research, Nottwil |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of a Polyhexanide Biguanide-Based Gel in the Prevention of Biofilm Formation in Pressure Ulcers (EARLY_PHASE1)
- Parasitic Ulcer Treatment Trial (PHASE3)
- Impact of Prontosan Wound Gel X on Surgical Site Infections in Cardiac Surgery
- Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.
- Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/ml Polihexanide
- UROtainer for Bladder Catheter Maintenance, Infection Prevention and Quality of Life (NA)
- Acetic Acid 2% Solution for Skin Ulcers (PHASE3)
- Ostomy Primary Closure With 0.1% Betaine/Polyhexanide Wound Irrigation Compared to Pursestring Closure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyhexanide CI brief — competitive landscape report
- Polyhexanide updates RSS · CI watch RSS
- Swiss Paraplegic Research, Nottwil portfolio CI